ACLARIS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.225 USD | +0.41% |
|
-6.49% | +16.67% |
| May. 07 | Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M | MT |
Presenter SpeechCorinne Jenkins (Analysts)Awesome. Well, thanks so much, everyone, for joining...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.225
USD
Average target price
1.84
USD
Spread / Average Target
+50.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 87.3M | |
| +23.37% | 47.02B | |
| +49.90% | 41.86B | |
| -0.94% | 41.76B | |
| -4.32% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Transcript : Aclaris Therapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 04